A

Agios Pharmaceuticals
D

AGIO

35.390
USD
-0.38
(-1.06%)
Market Closed
Volume
0
EPS
-6
Div Yield
-
P/E
3
Market Cap
2,018,298,601
Related Instruments
    B
    BLUE
    -0.69000
    (-7.52%)
    8.49000 USD
    E
    EXEL
    -0.390
    (-1.16%)
    33.280 USD
    I
    INCY
    1.910
    (2.85%)
    68.910 USD
    More
News

Title: Agios Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.